The estimated Net Worth of Matthew A. Spear is at least $178 Thousand dollars as of 6 December 2021. Dr Spear owns over 10,000 units of Poseida Therapeutics stock worth over $177,692 and over the last 4 years he sold PSTX stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dr Spear PSTX stock SEC Form 4 insiders trading
Dr has made over 9 trades of the Poseida Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of PSTX stock worth $13,200 on 6 December 2021.
The largest trade he's ever made was exercising 20,000 units of Poseida Therapeutics stock on 28 July 2021 worth over $26,400. On average, Dr trades about 6,680 units every 30 days since 2021. As of 6 December 2021 he still owns at least 61,485 units of Poseida Therapeutics stock.
You can see the complete history of Dr Spear stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Matthew A. Spear biography
Dr. Matthew A. Spear is the Chief Medical Officer at Poseida Therapeutics.
How old is Dr Spear?
Dr Spear is 54, he's been the Chief Medical Officer of Poseida Therapeutics since . There are 5 older and 4 younger executives at Poseida Therapeutics. The oldest executive at Poseida Therapeutics, Inc. is Harry J. Leonhardt Esq., J.D., 64, who is the Gen. Counsel, Chief Compliance Officer & Corp. Sec..
What's Dr Spear's mailing address?
Matthew's mailing address filed with the SEC is C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO, CA, 92121.
Insiders trading at Poseida Therapeutics
Over the last 4 years, insiders at Poseida Therapeutics have traded over $7,666,974 worth of Poseida Therapeutics stock and bought 3,065,405 units worth $15,916,632 . The most active insiders traders include David Hirsch, Life Sciences Holdings Ltd ..., and Eric Ostertag. On average, Poseida Therapeutics executives and independent directors trade stock every 18 days with the average trade being worth of $303,665. The most recent stock trade was executed by Eric Ostertag on 8 August 2022, trading 142,857 units of PSTX stock currently worth $500,000.
What does Poseida Therapeutics do?
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
What does Poseida Therapeutics's logo look like?
Complete history of Dr Spear stock trades at Poseida Therapeutics
Poseida Therapeutics executives and stock owners
Poseida Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Eric M. Ostertag,
CEO & Director -
Dr. Eric M. Ostertag M.D., Ph.D.,
Exec. Chairman -
Mark J. Gergen J.D.,
CEO & Director -
Mark J. Gergen,
Pres, Chief Bus. Officer & Director -
Harry J. Leonhardt,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Brent Warner,
Pres of Gene Therapy -
Harry J. Leonhardt Esq., J.D.,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Lisa Portale,
Sr. VP of Regulatory Affairs -
Dr. Matthew A. Spear,
Chief Medical Officer -
Dr. Devon J. Shedlock Ph.D.,
Chief Scientific Officer of Cell Therapies -
Sarah Thailing,
Director of Corp. Communications & IR -
Kristin Martin,
Chief People & Admin. Officer -
Kerry D. Ingalls,
Chief Operating Officer -
Johanna M. Mylet CPA,
Chief Financial Officer -
David Hirsch,
Director -
Catherine J Mackey,
Director -
John P. Schmid,
-
Sean Murphy,
Director -
Kristin Yarema,
President and CEO -
Life Sciences Holdings Ltd ...,
-
Pharma Agnovartis Ag Novartis,
-
Rafael Amado,
-
Matthew A. Spear,
Chief Medical Officer -
Kerry D. Ingalls,
Chief Operating Officer -
Harry J Leonhardt,
GC & Chief Compliance Officer -
Brent Warner,
President, Gene Therapy -
Luke Corning,
-
Johanna Mylet,
Chief Financial Officer -
Eric Ostertag,
Director -
Mark J Gergen,
Executive Chairman -
Life Sciences Holdings Ltd ...,
10% owner -
Charles M Baum,
-
Cynthia Collins,
-
Marcea Bland Lloyd,
-
Syed Ali Aamir Rizvi,
Chief Medical Officer